CANADA LIFE ASSURANCE Co Decreases Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

CANADA LIFE ASSURANCE Co lessened its position in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 1.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 86,043 shares of the life sciences company’s stock after selling 854 shares during the period. CANADA LIFE ASSURANCE Co owned about 0.11% of Integra LifeSciences worth $1,951,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Quadrant Capital Group LLC boosted its stake in Integra LifeSciences by 5,960.9% during the 4th quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company’s stock valued at $32,000 after purchasing an additional 1,371 shares during the last quarter. Sterling Capital Management LLC boosted its position in shares of Integra LifeSciences by 821.7% during the fourth quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company’s stock valued at $49,000 after buying an additional 1,931 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in Integra LifeSciences by 599.6% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock worth $74,000 after buying an additional 2,800 shares in the last quarter. Covestor Ltd raised its position in Integra LifeSciences by 61.8% in the 4th quarter. Covestor Ltd now owns 5,423 shares of the life sciences company’s stock worth $123,000 after buying an additional 2,071 shares during the last quarter. Finally, Empowered Funds LLC bought a new position in Integra LifeSciences during the 4th quarter valued at about $180,000. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Stock Performance

Shares of Integra LifeSciences stock opened at $16.81 on Monday. Integra LifeSciences Holdings Co. has a 12 month low of $14.45 and a 12 month high of $32.66. The stock’s fifty day moving average price is $20.51 and its 200-day moving average price is $22.23. The firm has a market cap of $1.30 billion, a P/E ratio of -186.76, a P/E/G ratio of 0.73 and a beta of 1.24. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.12. The business had revenue of $442.65 million during the quarter, compared to the consensus estimate of $445.15 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm’s revenue was up 11.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.89 earnings per share. On average, equities research analysts expect that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on IART. Truist Financial lowered their price objective on shares of Integra LifeSciences from $26.00 to $19.00 and set a “hold” rating on the stock in a research report on Friday, April 11th. Argus upgraded Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Monday, March 31st. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, Integra LifeSciences presently has an average rating of “Hold” and an average price target of $22.71.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.